We have analysed the genetic alteration of the entire coding region and all splice sites of caspase-8 and -10 genes in 99 gastric cancers by polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) and sequencing. We found LOH of the caspase-8 and -10 in nine (28%) of 32 and in four (15%) of 26 informative cases, respectively. Overall, three of 99 gastric cancers (3%) were found to have the caspase-10 mutations, which were identi®ed in the coding regions of the death eector domain (codon 147) and the p17 large protease domain (codons 257 and 410), whereas no mutation was detected in caspase-8. In vitro expression studies, the M147T and Q257stop mutants severely impaired caspase-10-mediated apoptosis, whereas the V410I which was the same mutation detected in ALPS patient had a signi®cant, albeit less severe, eect on apoptosis. The data presented here suggest that somatic alterations of the caspase-10 gene might contribute to the pathogenesis in a subset of gastric cancers through the loss of their apoptotic function.
Introduction
Accumulation of abnormal numbers of a clonally related population (neoplasm) can result from either uncontrolled proliferation or inhibition of cell death. The death receptor-ligand systems such as Fas-Fas receptor, TNF-TNF receptor, and TRAIL-TRAIL receptor are important pathways for the negative growth regulation of cells and tissues. Binding of death receptor by its agonistic antibodies or by its ligand induces the self-association of a conserved cytoplasmic region of death receptor called the death domain. This death receptor homotrimer interacts with a protein called Fas-associated death domain (FADD) containing another death domain and recruits the inactive procaspase-8 and/or -10 by FADD molecule and forms death-induced signaling complex (DISC). Aggregation of procaspase-8 and/or -10 in DISC initiates autoprocessing and release of active form of caspase-8 and -10 into the cytoplasm, where a proteolytic cascade leads to apoptosis (FernandesAlnemri et al., 1996; Ng et al., 1999; Vincenz and Dixit, 1997; Wang et al., 1999) . Disruption of this process may result in illegitimate cell survival and contribute to several human diseases including autoimmune lymphoproliferative syndrome (ALPS) or neoplasia (Nagata, 1997; Thompson, 1995) .
ALPS (autoimmune lymphoproliferative syndrome) is an inherited disease associated with germline mutation of either Fas (ALPS type Ia) or its ligand FasL (ALPS type Ib), which result in marked overaccumulation of mature lymphocytes and profound lymphadenopathy due to failure of Fas-mediated apoptosis. Recently Wang et al. (1999) reported germline mutation of caspase-10 gene in two kindreds with ALPS type II, but not of other death-related genes such as Fas, FasL, TNF receptor-1, FADD, TRADD, RIP, caspases-7, -8 or -9. Thus, they concluded that caspase-10 was the gene responsible for the ALPS type II phenotype in these pedigrees.
Gastric cancer occurs with a high incidence in Asia including Korea and is one of the leading causes of cancer death in the world. However, the molecular pathogenesis of gastric cancer is still unclear. There are accumulating evidences that human cancers including gastric cancer cells have escape mechanisms from death receptor-mediated apoptosis such as the mutations of primary structure of death receptors (Grùnbñk et al., 1998; Fisher et al., 1995; Landowsky et al., 1997; Lee et al., 1999; Shin et al., 1999; Park et al., 2001) , the production of soluble Fas (Lee et al., 1998b) , and ampli®cation of a decoy receptor (Pitti et al., 1998) . In addition, chromsome 2q33, where the caspases-8 and -10 genes reside (Fernandes-Alnemri et al., 1996) , has been reported as a commonly deleted region in gastric cancer (Nishizuka et al., 1998) and lung cancer (Otsuka et al., 1996) . It has also been reported that caspase-8 is frequently inactivated through DNA methylation as well as mutation in neuroblastoma cell lines (Takita et al., 2001) . Because caspases-8 and -10 are important Oncogene (2002) 
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components in a caspase cascading system as initiator caspases, genetic alteration of the primary structure of caspase-8 and -10 genes might also be one of the possible mechanisms disrupting apoptosis in gastric cancer cells.
In this study, we performed a PCR-based LOH and mutational analysis of caspase-8 and -10 genes on a series of 99 gastric cancers to determine whether mutations of these genes could be involved in gastric cancer development. And we also performed sitedirected mutagenesis and transfection assay to determine whether mutants detected in this study are functionally defective.
Results

Allelic status
We identi®ed a novel polymorphic site at nucleotide position 960 G/A (exon 9) of the caspase-8 gene and we used this as an intragenic polymorphic marker of caspase-8 gene for LOH analysis. In 63 normal healthy persons, 40 (63.5%) were homozygotes of G/G type and four (6.4%) revealed homozygote of the A/A genotype. Heterozygotes (G/A genotype) were seen in 19 (30.1%) persons. Of 99 gastric cancers, 32 cases (32%) were informative for this intragenic polymorphic marker and nine (28%) of them showed one allelic loss ( Figure 1a) .
Unfortunately, we could not detect any heterozygosity at nucleotide position 1337A/G of the caspase-10 gene in Korean gastric cancer patients, which has been reported by Wang et al. (1999) as a biallelic polymorphic site. Even though the heterozygosity rate of the exon 2 polymorphic site (177 G/A) of caspase-10 gene is quite low (26%), we used this as a LOH marker and demonstrated 15% of LOH (four of 25 informative) at this site. Interestingly, one of the cases with the caspase-10 mutation was heterozygous for polymorphic marker (177G/A) and showed the remaining allelic loss in tumor on SSCP analysis (Figures 1b and 2) . Unfortunately, however, two remaining cases with caspase-10 mutation were non-informative but they showed both mutant and wild-type bands in SSCP analysis, indicating the evidence of retention of heterozygosity (Figure 2) . Interestingly, one (case 35) of the cases with LOH at caspase-8 also demonstrated LOH at caspase-10.
Caspases-8 and -10 genes mutations Genomic DNAs extracted from gastric cancer cells and corresponding normal cells were analysed for potential mutations in all the coding region of the caspase-8 (exons 3 ± 10) and -10 (exons 2 ± 11) genes by PCR ± SSCP analysis, respectively. Enrichment and direct sequence analysis of aberrantly migrating bands led to the identi®cation of caspase-10 mutations in three (3%) of the samples (Figure 2 ). Two of them were missense mutation and the remaining one was nonsense (Figure 2 ), indicating the mutations in these specimens had risen somatically. All of the three mutations were reproducible through triplicate experiments including tissue microdissection, PCR, SSCP and sequencing analysis, which ensured the speci®city of the results.
In caspase-8 analysis, there was no aberrant band on the SSCP gel, suggesting absence of mutation of the caspase-8 gene in gastric cancers.
Loss of apoptotic activity by caspase-10 mutants
To determine whether these mutations detected in gastric cancer result in the loss of function of caspase-10, we transiently transfected the wild-type or mutant cDNA into 293 human kidney embryonal cell (293-cell). The transient transfection eciency was more than 80% in our experiment. And we con®rmed transfectants by Western blotting with anti-Myc antibody (Figure 3a) . The cells transfected with wild-type caspase-10 revealed signi®cant cell death and classic morphologic signs of apoptosis at 24 h after transfection ( Figure 3b ) and the percentage of apoptotic cells was 59.3+1.5% (Figure 3c ). However, the percentages of apoptotic cells in 293-cell transfected with M147T, Q257stop, or V410I of tumor-derived caspase-10 mutants were 26.3+5.5, 24.8+4.7, and 34.6+3.7%, respectively (Figure 3c) . Statistically, the apoptotic rates were signi®cantly decreased compared to those of wild-type caspase-10 (one-way ANOVA and Duncan's multiple range test, P50.01). The same series of transfection studies were carried out three times.
Discussion
As the concept of cancer as an apoptotic disease is gaining ground (Wyllie et al., 1999) , it is important to evaluate the genetic alteration of the apoptosisassociated gene in cancers. For example, mutations of death receptors such as Fas or KILLER/DR5 have been described not only in lymphoid-lineage malignancies but also in solid tumors including gastric cancer Park et al., 2001; Shin et al., 1999) . Furthermore, gastric cancer cells frequently express both FasL and Fas, but did not show apoptosis, suggesting the presence of other inhibiting mechanism of receptor-mediated apoptosis in gastric cancer. Moreover, gastric cancer is one of the human tumors with frequent LOH at chromosome 2q33 where the caspase-8 and -10 genes reside (Nishizuka et al., 1998) . Because caspase-8 and -10 have been demonstrated to associate with the death receptors, these are presumably initiator caspases in caspase cascade which act as executioner in death signaling. Therefore, genetic alterations of these cysteine proteases might also be one of dysregulating mechanisms of receptor-mediated apoptosis in gastric cancer.
In the present study, we detected three somatic mutations in caspase-10, but not in caspase-8 gene. Among the three mutations, two were missense (codons 147 and 410) and one was nonsense mutation (codon 257). Caspase-10 is present as an inactive proenzyme comprising a prodomain that contains two death eector domains (DED) to allow caspase-10 to interact with DED of FADD and a catalytic protease domain that can be further processed to give a large (p17) and a small subunit (p12). And it has been reported that caspase-10 lacking the DEDs did not bind FADD, suggesting that the DED is necessary for the transduction of an apoptotic signal. One mutant found in this study located at the second death eector domain with the change from the highly hydrophobic methionine to the hydrophilic threonine (M147T), showed severely impaired caspase function in cell death assay. Therefore this amino acid change might lead to structural change of prodomain of caspase-10 and prevent the DED-DED interaction between FADD and caspase-10.
The remaining two mutations were identi®ed in the coding region of the p17 large subunits of the protease. One nonsense mutation in case 59 having a C to T transition at bp 769 leads to a termination at codon 257 (Q257stop), resulting in a protein that is truncated shortly after the DED-containing prodomain. This truncated mutant might be similar to short form of FLICE-inhibitory protein (FLIPs) which contains only two death eector domains without catalytic domain and hence resembles typical loss-of-function mutation, in vitro expression studies, Q257stop mutation severely impairs caspase-10-mediated apoptosis as shown in Figure 3 .
We also found one missense mutation V410I in the p17 large subunit of the protease. Although Grùnbñk et al. (2000) has reported that the V410I (G1228A) variant of the caspase-10 gene is a common polymorphism in the Danish population, we considered this variant as a mutation by following evidences: (1) the variant was not detected in corresponding normal DNA of this patient as well as the other 98 normal DNAs of gastric cancer samples; (2) this mutant also revealed a signi®cant defect in caspase-10-mediated apoptosis in our study, and (3) this was the same mutation that was detected in ALPS patient (Wang et al., 1999) . Therefore all the mutations detected in this study seem to be a loss-of-function mutation which might lead to the loss of its apoptotic signaling function and contribute to the pathogenesis in a subset of gastric cancers.
There is a DED-caspase gene cluster on human chromosome 2q33-34 which contains the genes for FLICE-inhibitory protein (FLIP), caspase-8 and -10, suggesting that all of these genes have arisen by tandem duplication (Fernandes-Alnemri et al., 1996; Kohno et al., 1994) . This region, 2q33, was commonly deleted in several cancers such as gastric cancer (Nishizuka et al., 1998) , small cell lung cancer (Kohno et al., 1994) , and neuroblastoma (Takita et al., 2001 ). In our LOH study, however, we have detected only 15% (four of 26 informative) of LOH frequency of the caspase-10 gene. This low LOH frequency might be due to low frequency of heterozygosity rate of the new intragenic polymorphic marker used in this study. Among these, one case with caspase-10 mutation (M147T) revealed loss of the remained allele (case 78). Unfortunately, however, two cases with mutation (cases 12 and 59) showed non-informative in LOH study.
In analysis of the alterations of the caspase-8 gene in gastric cancers, only allelic loss was detected in nine (28%) of 32 informative cases, without any mutation. The absence of mutation in the caspase-8 gene makes it unclear as to whether it is a true tumor suppressor gene involved in gastric cancer development. Up to date, there has been reported only two missense mutations of caspase-8 gene, one in a head and neck cancer (Mandruzzato et al., 1997) and the other in a neuroblastoma cell line (Takita et al., 2001) . However, Tetz et al. (2000) described that inactivation of caspase-8 gene occurred frequently through DNA methylation as well as gene deletion, but not through mutation. In addition, loss of caspase-8 expression correlates to tumor severity and resistance to TRAIL-induced apoptosis (Hopkins-Donaldson et al., 2000) . Therefore, additional methylation study is needed to verify whether methylation might be one of the inactivating mechanisms of caspase-8 gene in gastric cancer.
Despite in the small number of cases, because we were able to detect mutations of caspase-10 gene in gastric cancer and these mutants revealed impairment of its apoptotic function, we concluded that mutations of caspase-10 gene may be another mechanism for gastric cancer cell protection through apoptosis resistance, which may have resulted in their prolonged lifespan and have a further chance to get other gene mutations and thus play an important role in tumor promotion and/or progression in a subset of gastric cancer.
Materials and methods
Tissue samples and microdissection
A total of 99 paran-embedded sporadic gastric carcinoma specimens were obtained from College of Medicine, The Catholic University of Korea. No patient had a family history of gastric cancer. Hematoxylin and Eosin (H and E) stained histological sections were reviewed in each case. Tumors were classi®ed according to Lauren's criteria (Lauren, 1965) . Fifty-®ve carcinomas were of the intestinal type and 44 tumors of the diuse type.
Malignant cells were selectively procured from H and E stained slides without any normal cell contamination using a 30G1/2 hypodermic needle (Becton Dickinson, Franklin Lakes, NJ, USA) axed to a microdissection device (SPEM II, Simple, Precise and Economical Microdissection device; BioKhan Int. Co., Seoul, Korea), as described previously (Lee et al., 1998a) . We also obtained surrounding normal gastric mucosa cells for corresponding normal DNA from the same slides in all cases. DNA extraction was performed by a modi®ed single-step DNA extraction method, as described previously (Lee et al., 1998a) .
Single strand conformation polymorphism (SSCP) analysis
Genomic DNAs from tumor cells and corresponding normal cells were ampli®ed with 13 and 15 primer pairs covering the entire coding region of the caspase-8 and -10 gene, respectively (Table 1) . Numbering of nucleotide of caspases-8 and -10 was done in respect to the ATG start codon of caspases-8 and -10. Each polymerase chain reaction (PCR) was performed under standard conditions in a 10 ml reaction mixture containing 1 ml of template DNA, 0.5 mM of each primer, 0.2 mM of each deoxynucleotide triphosphate, 1.5 mM MgCl 2 , 0.4 unit of Ampli Taq gold polymerase (PerkinElmer, Foster City, CA, USA), 0.5 mCi of [ 32 P]dCTP (Amersham, Buckinghamshire, UK), and 1 ml of 106buer. The reaction mixture was denatured for 1 min at 948C and incubated for 35 cycles (denaturing for 40 s at 948C, annealing for 40 s at 59 ± 688C, and extending for 40 s at 728C). Final extension was continued for 5 min at 728C. After ampli®cation, PCR products were denatured for 5 min at 958C at a 1 : 1 dilution of sample buer containing 98% formamide/5 mmol/L NaOH and were loaded onto a SSCP gel (FMC Mutation Detection Enhancement system; Intermountain Scienti®c, Kaysville, UT, USA) with 10% glycerol. Samples were electrophoresed at 8 W at room temperature overnight. After electrophoresis, the gels were transferred to 3-mm Whatman paper and dried, and autoradiography was performed with Kodak X-OMAT ®lm (Eastman Kodak, Rochester, NY, USA). For the detection of mutations, DNAs showing aberrant mobility shifts were cut out from the dried gel, and re-ampli®ed for 30 cycles using the same primer set. Sequencing of the PCR products was carried out using the cyclic sequencing kit (Perkin-Elmer, Foster City, CA, USA) according to the manufacturer's recommendation.
LOH analysis
Biallelic polymorphism at nucleotide position 1337 A/G (exon 9) in the caspase-10 gene has been reported (Wang et al., 1999) . In this study, we also found two novel polymorphic sites during the SSCP and sequencing analysis in exon 9 of caspase-8 and exon 2 of caspase-10. Sequencing frequently revealed an exchange of guanine with adenosine at nucleotide position 960 from the ATG start codon of caspase-8 and at position 177 of caspase-10. The PCR and SSCP conditions for LOH study were the same as the conditions described above. Complete absence of one allele in tumor DNA of informative cases, as de®ned by direct visualization, was considered as LOH.
Site-directed mutagenesis
Site-directed mutagenesis was performed using a Quick change site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instruction. To change a base, plasmid that contained either the full-length caspase-10 in pcDNA3.1-myc (Invitrogene, Carlsbad, CA, USA) was used as a template. The sequences of the mutagenized plasmids were con®rmed by direct sequencing (data not shown).
Cell culture, transfection, and apoptosis assay 293-cells, primary human embryonal kidney cells transformed by human adenovirus type 5 were maintained in EMEM (BioWhittaker, Walkersville, MD, USA) supplemented with 10% FBS, 1 mM L-glutamine and antibiotics. 293-cells (10 6 ) were plated per well in two-chamber slide and transfected by the Superfect transfection reagent (Qiagen, Valencia, CA, USA) with 1.3 mg of the wild-type or mutant gene constructs of caspase-10 with 0.2 mg of green¯uorescence protein (GFP) marker plasmid pEGFP (CLONTECT, Palo Alto, CA, USA). The cell lysates were analysed by Western blotting with anti-MYC antibody and con®rmed the expression of transfected Caspase-10 (Figure 3a) . At 48 h after transfection, quantitation of apoptosis was done by manually counting the percentage of fragmented nuclei in GFPexpressing cells under¯uorescence microscopy after ®xing in 10% methanol for 15 min and staining with 0.1 mg/ml 4'-diamidino-2-phenylindole for 15 min (Figure 3b ). Data is presented as the mean+s.d. of ®ve independent experiments (Figure 3c ).
